Giuseppe Saglio

Research interests

Publications

• European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

  Leukemia · 2020 · 10.1038/s41375-020-0776-2

• Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

  Leukemia · 2016 · 10.1038/leu.2016.5

• Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2015.64.8899

• Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients: a nationwide retrospective survey from Italy

  Bone Marrow Transplantation · 2014 · https://doi.org/10.1038/bmt.2014.231

• Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

  Blood · 2013 · https://doi.org/10.1182/blood-2013-06-511592

• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

  Blood · 2013 · 10.1182/blood-2013-05-501569

• Standardized definitions of molecular response in chronic myeloid leukemia

  Leukemia · 2012 · 10.1038/leu.2012.104

• Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

  Leukemia · 2012 · 10.1038/leu.2012.134

• Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

  The Lancet Oncology · 2011 · https://doi.org/10.1016/s1470-2045(11)70201-7

• BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

  Blood · 2011 · 10.1182/blood-2010-12-326405

• Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

  New England Journal of Medicine · 2010 · 10.1056/nejmoa0912614

• Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results

  Blood · 2010 · 10.1182/blood-2010-03-277152

• Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

  Blood · 2009 · https://doi.org/10.1182/blood-2008-12-191254

• Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.22.4865

• Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

  Journal of Clinical Oncology · 2009 · 10.1200/jco.2009.25.0779

• Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

  Blood · 2008 · 10.1182/blood-2008-04-150680

• PML targeting eradicates quiescent leukaemia-initiating cells

  Nature · 2008 · 10.1038/nature07016

• Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

  Clinical Cancer Research · 2006 · 10.1158/1078-0432.ccr-06-1516

• Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis

  Blood · 2006 · https://doi.org/10.1182/blood-2006-09-046888

• Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations

  Leukemia · 2006 · https://doi.org/10.1038/sj.leu.2404149

• Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

  New England Journal of Medicine · 2006 · 10.1056/nejmoa062867

• Cytoplasmic Nucleophosmin in Acute Myelogenous Leukemia with a Normal Karyotype

  New England Journal of Medicine · 2005 · 10.1056/nejmoa041974

• Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – A Europe Against Cancer Program

  Leukemia · 2003 · 10.1038/sj.leu.2403135

• Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

  New England Journal of Medicine · 2003 · 10.1056/nejmoa022457

• Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe against cancer program

  Leukemia · 2003 · 10.1038/sj.leu.2403136

• Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease

  Leukemia · 1999 · 10.1038/sj.leu.2401592

• Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne dell'Adulto and Associazione Italiana di Ematologia ed Oncologia Pediatrica Cooperative Groups.

  PubMed · 1997 · https://doi.org/10.1182/blood.v90.3.1014

• Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction) [see comments]

  Blood · 1996 · 10.1182/blood.v88.7.2410.bloodjournal8872410

Current projects

No projects listed.